ERBB2 and neoplasm: HER2 is an oncoprotein that is necessary to initiate the tumor, as it is expressed in premalignant lesions, but is not sufficient to promote cancer progression and dissemination, as it requires the presence of other molecular alterations14 In this context, the identification of additional vulnerabilities beyond the mere presence of HER2 is a main objective.